Precision Biosciences (DTIL) Amortizatization of Intangibles (2020 - 2026)
Precision Biosciences (DTIL) reported Amortizatization of Intangibles of $341000.0 for Q1 2026, up 10.0% year-over-year from $310000.0 in Q1 2025, and up 2.4% on a QoQ basis from $333000.0 in Q4 2025.
Precision Biosciences (DTIL) has 7 years of Amortizatization of Intangibles data on file, last reported at $341000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 10.0% year-over-year to $341000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 9.76% YoY) and the FY2025 annual result came in at $1.3 million, up 9.55% from the prior year.
- Amortizatization of Intangibles improved to $341000.0 in Q1 2026 per DTIL's latest filing, from $333000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $615000.0 in Q3 2024 and bottomed at -$430000.0 in Q3 2023.
- The 5-year median for Amortizatization of Intangibles is $297000.0 (2022), against an average of $203647.1.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles tumbled 221.36%; it then soared 1196.55% in 2025.
- Tracing DTIL's Amortizatization of Intangibles over 5 years: stood at $85000.0 in 2022, then tumbled by 37.65% to $53000.0 in 2023, then soared by 471.7% to $303000.0 in 2024, then advanced by 9.9% to $333000.0 in 2025, then rose by 2.4% to $341000.0 in 2026.
- Per Business Quant, the three latest DTIL Amortizatization of Intangibles figures stand at $341000.0 (Q1 2026), $333000.0 (Q4 2025), and $324000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | 341,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 341,000.00 |
| Mar 31, 2026 | 341,000.00 |
| Dec 31, 2025 | 333,000.00 |
| Dec 31, 2025 | 333,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 318,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Dec 31, 2024 | 303,000.00 |
| Dec 31, 2024 | 303,000.00 |
| Sep 30, 2024 | 615,000.00 |
| Sep 30, 2024 | 615,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2024 | 284,000.00 |
| Mar 31, 2024 | 284,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Sep 30, 2023 | -430,000.00 |
| Sep 30, 2023 | -430,000.00 |
| Jun 30, 2023 | 532,000.00 |
| Jun 30, 2023 | 532,000.00 |
| Mar 31, 2023 | 213,000.00 |
| Mar 31, 2023 | 213,000.00 |
| Dec 31, 2022 | 85,000.00 |
| Dec 31, 2022 | 85,000.00 |
| Sep 30, 2022 | -375,000.00 |
| Sep 30, 2022 | -375,000.00 |
| Jun 30, 2022 | 297,000.00 |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Dec 31, 2021 | 1.17 Mn |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | 309,000.00 |
| Sep 30, 2021 | 309,000.00 |
| Jun 30, 2021 | 298,000.00 |
| Jun 30, 2021 | 298,000.00 |
| Mar 31, 2021 | 290,000.00 |
| Mar 31, 2021 | 290,000.00 |
| Dec 31, 2020 | 281,000.00 |
| Dec 31, 2020 | 281,000.00 |
| Sep 30, 2020 | 270,000.00 |
| Sep 30, 2020 | 270,000.00 |
| Jun 30, 2020 | 250,000.00 |
| Jun 30, 2020 | 250,000.00 |
| Mar 31, 2020 | 235,000.00 |
| Mar 31, 2020 | 235,000.00 |